Artificial intelligence continues to transform drug discovery and genomics through innovative platforms and partnerships. Nanyang Biologics merged with Nasdaq-listed RF Acquisition Corp II to scale its AI-driven natural compound drug discovery valued at $1.5 billion. IDT and Hamilton joined forces to automate customizable next-generation sequencing workflows, enabling scalable and precise genomic discoveries. Additionally, advanced protein language models and multimodal AI facilitate integrated analysis, accelerating therapeutic target identification and biomarker development.